These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15910010)

  • 1. Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients.
    Sánchez Navarro A; Colino Gandarillas CI; Alvarez Lerma F; Menacho YA; Domínguez-Gil A
    Clin Pharmacokinet; 2005; 44(6):627-35. PubMed ID: 15910010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
    Preston SL; Drusano GL; Berman AL; Fowler CL; Chow AT; Dornseif B; Reichl V; Natarajan J; Wong FA; Corrado M
    Antimicrob Agents Chemother; 1998 May; 42(5):1098-104. PubMed ID: 9593134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia.
    Pea F; Di Qual E; Cusenza A; Brollo L; Baldassarre M; Furlanut M
    Clin Pharmacokinet; 2003; 42(6):589-98. PubMed ID: 12793843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit.
    Rebuck JA; Fish DN; Abraham E
    Pharmacotherapy; 2002 Oct; 22(10):1216-25. PubMed ID: 12389872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae.
    Ambrose PG; Grasela DM
    Diagn Microbiol Infect Dis; 2000 Nov; 38(3):151-7. PubMed ID: 11109013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
    Frei CR; Burgess DS
    Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer.
    Sowinski KM; Lucksiri A; Kays MB; Scott MK; Mueller BA; Hamburger RJ
    Am J Kidney Dis; 2003 Aug; 42(2):342-9. PubMed ID: 12900817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.
    Chien SC; Wong FA; Fowler CL; Callery-D'Amico SV; Williams RR; Nayak R; Chow AT
    Antimicrob Agents Chemother; 1998 Apr; 42(4):885-8. PubMed ID: 9559801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.
    Chien SC; Chow AT; Rogge MC; Williams RR; Hendrix CW
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1765-9. PubMed ID: 9257757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae.
    Nicolau DP; Ambrose PG
    Am J Med; 2001 Dec; 111 Suppl 9A():13S-18S; discussion 36S-38S. PubMed ID: 11755438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data.
    Burgess DS; Hall RG
    Clin Ther; 2007 Jul; 29(7):1421-7. PubMed ID: 17825693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
    Noreddin AM; Marras TK; Sanders K; Chan CK; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2004 Nov; 24(5):479-84. PubMed ID: 15519481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of gatifloxacin pharmacokinetics and pharmacodynamics in severely ill adults in a medical Intensive Care Unit.
    Fish DN
    Int J Antimicrob Agents; 2007 Jun; 29(6):715-23. PubMed ID: 17433631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.
    Chien SC; Rogge MC; Gisclon LG; Curtin C; Wong F; Natarajan J; Williams RR; Fowler CL; Cheung WK; Chow AT
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2256-60. PubMed ID: 9333057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia.
    Boselli E; Breilh D; Rimmelé T; Djabarouti S; Saux MC; Chassard D; Allaouchiche B
    Crit Care Med; 2005 Jan; 33(1):104-9. PubMed ID: 15644655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa.
    Deguchi T; Seike K; Yasuda M; Matsumoto T
    J Infect Chemother; 2011 Oct; 17(5):726-30. PubMed ID: 21409530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients.
    Traunmüller F; Thalhammer-Scherrer R; Locker GJ; Losert H; Schmid R; Staudinger T; Thalhammer F
    J Antimicrob Chemother; 2001 Feb; 47(2):229-31. PubMed ID: 11157914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation.
    Drusano GL; Preston SL; Gotfried MH; Danziger LH; Rodvold KA
    Antimicrob Agents Chemother; 2002 Feb; 46(2):586-9. PubMed ID: 11796385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.
    Kiser TH; Hoody DW; Obritsch MD; Wegzyn CO; Bauling PC; Fish DN
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1937-45. PubMed ID: 16723549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
    Zhang J; Xu JF; Liu YB; Xiao ZK; Huang JA; Si B; Sun SH; Xia QM; Wu XJ; Cao GY; Shi YG; Zhang YY
    J Infect Chemother; 2009 Oct; 15(5):293-300. PubMed ID: 19856067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.